Skip to main content
SpringerLink
Log in

Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Arterial stiffness is an independent predictor of cardiovascular (CV) morbidity and mortality in patients with hypertension, as well as a potential therapeutic target. There is increasing awareness that the pulsatile hemodynamics (central blood pressure [CBP], pulse pressure [PP], wave reflections [augmentation index or AIx] and pulse wave velocity [PWV]) may provide better insight into the pathophysiology of CV disorders and target organ damage related to hypertension. Different antihypertensive drugs produce diverse effects on arterial stiffness variables, despite similar effects on peripheral (brachial) blood pressure. Identifying the pharmacologic interventions that can improve arterial stiffness (‘de-stiffening’ treatment) is a promising field of research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006 Nov; 27(21): 2588–605

    Google Scholar 

  2. McEniery CM, Yasmin, McDonnell B, et al. Anglo-Cardiff Collaborative Trial Investigators. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension 2008 Jun; 51(6): 1476–82

    CAS  Google Scholar 

  3. Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis 2010 Feb; 20(2): 140–6

    Article  PubMed  CAS  Google Scholar 

  4. Goch A, Banach M, Mikhailidis DP, et al. Endothelial dysfunction in patients with non complicated and complicated hypertension. Clin Exp Hypertens 2009 Feb; 31(1): 20–30

    Article  PubMed  CAS  Google Scholar 

  5. Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007 Sep; 11(9): 1143–60

    Article  PubMed  CAS  Google Scholar 

  6. Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010 Nov; 74(11): 2257–62

    Article  PubMed  Google Scholar 

  7. Rossi P, Francès Y, Kingwell BA, et al. Gender differences in artery wall biomechanical properties throughout life. J Hypertens 2011 Jun; 29(6): 1023–33

    Article  PubMed  CAS  Google Scholar 

  8. McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 2007 Jul; 34(7): 665–71

    Article  PubMed  CAS  Google Scholar 

  9. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008 Apr; 51(4): 527–39

    Article  PubMed  CAS  Google Scholar 

  10. Seifalian AM, Filippatos TD, Joshi J, et al. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010 Mar; 8(2): 155–68

    Article  PubMed  CAS  Google Scholar 

  11. Doonan RJ, Hausvater A, Scallan C, et al. The effect of smoking on arterial stiffness. Hypertens Res 2010 May; 33(5): 398–410

    Article  PubMed  Google Scholar 

  12. Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension 1999 Sep; 34(3): 386–7

    Article  PubMed  CAS  Google Scholar 

  13. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study. Am J Cardiol 1971 Apr; 27(4): 335–46

    Article  PubMed  CAS  Google Scholar 

  14. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, et al., Aortic Blood Pressure and Survival Study Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008 Apr; 51(4): 848–55

    Article  PubMed  CAS  Google Scholar 

  15. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007 Jul; 50(1): 197–203

    Article  PubMed  CAS  Google Scholar 

  16. Agabiti-Rosei E, Mancia G, O’Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007 Jul; 50(1): 154–60

    Article  PubMed  CAS  Google Scholar 

  17. Katsiki N, Koumaras C, Athyros VG, et al. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012 Jan; 63(1): 9–11

    Article  PubMed  Google Scholar 

  18. Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003 May; 34(5): 1203–6

    Article  PubMed  Google Scholar 

  19. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010 Feb; 121(4): 505–11

    Article  PubMed  Google Scholar 

  20. Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004 Feb; 17(2): 118–23

    Article  PubMed  CAS  Google Scholar 

  21. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006 Jul; 48(1): 80–6

    Article  PubMed  CAS  Google Scholar 

  22. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960 Jan; 21: 21–7

    Article  PubMed  CAS  Google Scholar 

  23. Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008 Feb; 26(2): 351–6

    Article  PubMed  CAS  Google Scholar 

  24. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19(6): 540–56

    Article  PubMed  CAS  Google Scholar 

  25. Kontopoulos AG, Athyros VG, Pehlivanidis AN, et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003; 19(1): 22–7

    Article  PubMed  CAS  Google Scholar 

  26. Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010 Feb; 95(2): 722–30

    Article  PubMed  CAS  Google Scholar 

  27. Harashima K, Hayashi J, Miwa T, et al. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism 2009 Jun; 58(6): 739–45

    Article  PubMed  CAS  Google Scholar 

  28. Tanaka H, Munakata M, Kawano Y, et al. Comparison between carotidfemoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens 2009 Oct; 27(10): 2022–7

    Article  PubMed  CAS  Google Scholar 

  29. Tsuchikura S, Shoji T, Kimoto E, et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010 Jun; 17(6): 658–65

    Article  PubMed  Google Scholar 

  30. Hongo M, Kumazaki S, Izawa A, et al. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circ J 2011 Oct; 75(11): 2660–7

    Article  PubMed  CAS  Google Scholar 

  31. Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb 2011; 18(11): 924–38

    Article  PubMed  Google Scholar 

  32. Dolan E, Li Y, Thijs L, et al. Ambulatory arterial stiffness index: rationale and methodology. Blood Press Monit 2006 Apr; 11(2): 103–5

    Article  PubMed  Google Scholar 

  33. Van Bortel LM, Struijker-Boudier HA, Safar ME. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension 2001 Oct; 38(4): 914–21

    Article  PubMed  Google Scholar 

  34. Safar ME, Jankowski P. Antihypertensive therapy and de-stiffening of the arteries. Expert Opin Pharmacother 2010 Nov; 11(16): 2625–34

    Article  PubMed  CAS  Google Scholar 

  35. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2004 Sep; 5(3): 102–8

    Article  PubMed  CAS  Google Scholar 

  36. Protogerou AD, Papaioannou TG, Lekakis JP, et al. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part I: (Patho)-physiology, rationale and perspective on pulse pressure amplification. Curr Pharm Des 2009; 15(3): 267–71

    CAS  Google Scholar 

  37. van der Heijden-Spek JJ, Staessen JA, Fagard RH, et al. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study. Hypertension 2000 Feb; 35(2): 637–42

    Article  PubMed  Google Scholar 

  38. Kool MJ, Spek JJ, Struyker Boudier HA, et al. Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers. Cardiovasc Drugs Ther 1995 Apr; 9(2): 331–7

    Article  PubMed  CAS  Google Scholar 

  39. Laurent S, Arcaro G, Benetos A, et al. Mechanism of nitrate-induced improvement on arterial compliance depends on vascular territory. J Cardiovasc Pharmacol 1992 Apr; 19(4): 641–9

    Article  PubMed  CAS  Google Scholar 

  40. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003 Jun; 107(22): 2864–9

    Article  PubMed  Google Scholar 

  41. Mitchell GF, Lacourcière Y, Arnold JM, et al. Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. Hypertension 2005 Nov; 46(5): 1111–7

    Article  PubMed  CAS  Google Scholar 

  42. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data. Hypertension 2009 Aug; 54(2): 375–83

    Article  PubMed  CAS  Google Scholar 

  43. Ahimastos AA, Natoli AK, Lawler A, et al. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005 Jun; 45(6): 1194–9

    Article  PubMed  CAS  Google Scholar 

  44. Wilkinson IB, McEniery CM. Arterial stiffness, endothelial function and novel pharmacological approaches. Clin Exp Pharmacol Physiol 2004 Nov; 31(11): 795–9

    Article  PubMed  CAS  Google Scholar 

  45. Bakris GL, Bank AJ, Kass DA, et al. Advanced glycation end-product crosslink breakers: a novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004 Dec; 17(12 Pt 2): 23S–30S

    Article  PubMed  CAS  Google Scholar 

  46. Shapiro BP, Owan TE, Mohammed SF, et al. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation 2008 Sep; 118(10): 1002–10

    Article  PubMed  CAS  Google Scholar 

  47. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001 Sep; 104(13): 1464–70

    Article  PubMed  CAS  Google Scholar 

  48. Avolio AP, Deng FQ, Li WQ, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985 Feb; 71(2): 202–10

    Article  PubMed  CAS  Google Scholar 

  49. Safar ME. Can antihypertensive treatment reverse large-artery stiffening?. Curr Hypertens Rep 2010 Feb; 12(1): 47–51

    Article  PubMed  Google Scholar 

  50. Dao HH, Essalihi R, Bouvet C, et al. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 2005 May; 66(2): 307–17

    Article  PubMed  CAS  Google Scholar 

  51. Kakou A, Bézie Y, Mercier N, et al. Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens 2009 Jul; 22(7): 711–7

    Article  PubMed  CAS  Google Scholar 

  52. Louis H, Kakou A, Regnault V, et al. Role of alpha1beta1-integrin in arterial stiffness and angiotensin-induced arterial wall hypertrophy in mice. Am J Physiol Heart Circ Physiol. 2007 Oct; 293(4): H2597–604

    Article  PubMed  CAS  Google Scholar 

  53. Bézie Y, Lamazière JM, Laurent S, et al. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1998 Jul; 18(7): 1027–34

    Article  PubMed  Google Scholar 

  54. Labat C, Lacolley P, Lajemi M, et al. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension 2001 Sep; 38(3): 439–43

    Article  PubMed  CAS  Google Scholar 

  55. Jankowski P, Safar ME, Benetos A. Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des 2009; 15(5): 571–84

    Article  PubMed  CAS  Google Scholar 

  56. Protogerou AD, Stergiou GS, Vlachopoulos C, et al. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des 2009; 15(3): 272–89

    CAS  Google Scholar 

  57. Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000 Jan; 35(1 Pt 2): 501–6

    Article  PubMed  CAS  Google Scholar 

  58. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001 Feb; 103(6): 799–805

    Article  PubMed  CAS  Google Scholar 

  59. Richer C, Bruneval P, Ménard J, et al. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension 1998 Feb; 31(2): 692–8

    Article  PubMed  CAS  Google Scholar 

  60. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000 Feb; 101(8): 844–6

    Article  PubMed  CAS  Google Scholar 

  61. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003 Jan; 16(1): 80–6

    Article  PubMed  CAS  Google Scholar 

  62. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000 Nov; 102(22): 2700–6

    Article  CAS  Google Scholar 

  63. Lacolley P, Labat C, Pujol A, et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002 Nov; 106(22): 2848–53

    Article  PubMed  CAS  Google Scholar 

  64. Jiang XJ, OśRourke MF, Jin WQ, et al. Quantification of glyceryl trinitrate effect through analysis of the synthesised ascending aortic pressure waveform. Heart 2002 Aug; 88(2): 143–8

    Article  PubMed  CAS  Google Scholar 

  65. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation 2002 Nov; 106(19): 2510–3

    Article  PubMed  Google Scholar 

  66. London GM, Asmar RG, OśRourke MF, et al. REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004 Jan; 43(1): 92–9

    CAS  Google Scholar 

  67. Karagiannis A, Mikhailidis DP, Kakafika AI, et al. Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome? Curr Pharm Des 2007; 13(2): 229–39

    Article  PubMed  CAS  Google Scholar 

  68. Williams B, Lacy PS, Thom SM, et al., CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 Mar; 113(9): 1213–25

    Article  PubMed  CAS  Google Scholar 

  69. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995 May; 25(5): 1034–41

    Article  PubMed  CAS  Google Scholar 

  70. Dhakam Z, McEniery CM, Yasmin, et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006 Feb; 19(2): 214–9

    Article  PubMed  CAS  Google Scholar 

  71. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009 Aug; 54(2): 409–13

    Article  PubMed  CAS  Google Scholar 

  72. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008 Jun; 21(6): 663–7

    Article  PubMed  CAS  Google Scholar 

  73. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004 Sep; 44(3): 305–10

    Article  PubMed  CAS  Google Scholar 

  74. Polónia J, Barbosa L, Silva JA, et al. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with b-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit 2010 Oct; 15(5): 235–9

    Article  PubMed  Google Scholar 

  75. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag 2009; 5(1): 353–60

    Article  PubMed  CAS  Google Scholar 

  76. Karagiannis A, Athyros VG, Papageorgiou A, et al. Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic J Cardiol 2006 Sep–Oct; 47(5): 298–307

    PubMed  Google Scholar 

  77. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 Oct–Nov; 366(9496): 1545–53

    Article  PubMed  CAS  Google Scholar 

  78. Pedersen ME, Cockcroft JR. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension? Curr Opin Cardiol 2009 Jul; 24(4): 325–32

    Article  PubMed  Google Scholar 

  79. Jiang XJ, OśRourke MF, Zhang YQ, et al. Superior effect of an angiotensinconverting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 2007 May; 25(5): 1095–9

    Article  PubMed  CAS  Google Scholar 

  80. Dart AM, Cameron JD, Gatzka CD, et al. Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension 2007 Jun; 49(6): 1242–7

    Article  PubMed  CAS  Google Scholar 

  81. Ting CT, Chen CH, Chang MS, et al. Short- and long-term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. Hypertension 1995 Sep; 26(3): 524–30

    Article  PubMed  CAS  Google Scholar 

  82. Topouchian J, Brisac AM, Pannier B, et al. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a doubleblind, comparative and crossover study. J Hum Hypertens 1998 Mar; 12(3): 181–7

    Article  PubMed  CAS  Google Scholar 

  83. de Luca N, Asmar RG, London GM, et al., REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004 Aug; 22(8): 1623–30

    Article  PubMed  Google Scholar 

  84. Kengne AP, Czernichow S, Huxley R, et al., ADVANCE Collaborative Group. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009 Aug; 54(2): 399–404

    Article  PubMed  CAS  Google Scholar 

  85. Dahlöf B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep; 366(9489): 895–906

    Article  PubMed  CAS  Google Scholar 

  86. Mitchell GF, Dunlap ME, Warnica W, et al., Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007 Jun; 49(6): 1271–7

    Article  PubMed  CAS  Google Scholar 

  87. Wing LM, Reid CM, Ryan P, et al., Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensinconverting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 Feb; 348(7): 583–92

    Article  PubMed  CAS  Google Scholar 

  88. Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension 2003 Feb; 41(2): 297–301

    Article  PubMed  CAS  Google Scholar 

  89. Aznaouridis KA, Stamatelopoulos KS, Karatzis EN, et al. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients. J Hum Hypertens 2007 Aug; 21(8): 654–63

    Article  PubMed  CAS  Google Scholar 

  90. London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994 Dec; 90(6): 2786–96

    CAS  Google Scholar 

  91. Lacourcière Y, Béliveau R, Conter HS, et al., Canadian Hypertension Society. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. Can J Cardiol 2004 Jun; 20(8): 795–9

    PubMed  Google Scholar 

  92. Pannier BM, Guerin AP, Marchais SJ, et al. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001 Dec; 28(12): 1074–7

    Article  PubMed  CAS  Google Scholar 

  93. Rehman A, Ismail SB, Naing L, et al. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition: a comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007 Feb; 20(2): 184–9

    Article  PubMed  CAS  Google Scholar 

  94. Topouchian J, Asmar R, Sayegh F, et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 1999 May; 30(5): 1056–64

    Article  PubMed  CAS  Google Scholar 

  95. Kaiser T, Heise T, Nosek L, et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006 Jul; 24(7): 1397–403

    Article  PubMed  CAS  Google Scholar 

  96. Deary AJ, Schumann AL, Murfet H, et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci 2002 Nov; 103(5): 493–9

    Article  PubMed  CAS  Google Scholar 

  97. Ali K, Rajkumar C, Fantin F, et al. Irbesartan improves arterial compliance more than lisinopril. Vasc Health Risk Manag 2009; 5(4): 587–92

    Article  PubMed  CAS  Google Scholar 

  98. Hirata K, Vlachopoulos C, Adji A, et al. Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery?. J Hypertens 2005 Mar; 23(3): 551–6

    Article  PubMed  CAS  Google Scholar 

  99. London GM, Pannier B, Vicaut E, et al. Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. J Hypertens 1996 Sep; 14(9): 1139–46

    Article  PubMed  CAS  Google Scholar 

  100. Ferguson JM, Minas J, Siapantas S, et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. J Cardiovasc Pharmacol 2008 Jun; 51(6): 590–5

    Article  PubMed  CAS  Google Scholar 

  101. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens 2000 Sep; 14(9): 541–6

    Article  PubMed  CAS  Google Scholar 

  102. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002 Apr; 15(4 Pt 1): 321–5

    Article  PubMed  CAS  Google Scholar 

  103. Klingbeil AU, John S, Schneider MP, et al. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 2002 Dec; 20(12): 2423–8

    Article  PubMed  CAS  Google Scholar 

  104. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008 Jun; 51(6): 1617–23

    Article  PubMed  CAS  Google Scholar 

  105. Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008 Jul; 23(7): 2280–5

    Article  PubMed  CAS  Google Scholar 

  106. Mediavilla García JD, Fernández-Torres C, Jaén Aguila F, et al. Effect of olmesartan medoxomil on arterial stiffness in patients with essential hypertension. Med Clin (Barc) 2007 May; 128(19): 726–9

    Article  Google Scholar 

  107. Matsui Y, Eguchi K, OśRourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009 Oct; 54(4): 716–23

    Article  PubMed  CAS  Google Scholar 

  108. Asmar R. Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus. J Renin Angiotensin Aldosterone Syst 2001 Sep; 2 Suppl. 2: S8–11

    Article  PubMed  CAS  Google Scholar 

  109. Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009 May; 39(5): 180–4

    Article  PubMed  CAS  Google Scholar 

  110. Mahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002 Dec; 15(12): 1092–5

    Article  PubMed  CAS  Google Scholar 

  111. Davies J, Carr E, Band M, et al. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?. J Renin Angiotensin Aldosterone Syst 2005 Dec; 6(3): 151–3

    Article  PubMed  CAS  Google Scholar 

  112. Dahlöf B, Devereux RB, Kjeldsen SE, et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar; 359(9311): 995–1003

    Article  PubMed  Google Scholar 

  113. Julius S, Kjeldsen SE, Weber M, et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun; 363(9426): 2022–31

    Article  PubMed  CAS  Google Scholar 

  114. Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006 Sep; 48(3): 385–91

    Article  PubMed  CAS  Google Scholar 

  115. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTI-MAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 Sep; 360(9335): 752–60

    CAS  Google Scholar 

  116. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005 Jan; 18(1): 50–5

    Article  PubMed  CAS  Google Scholar 

  117. Kithas PA, Supiano MA. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc 2010 Jul; 58(7): 1327–32

    Article  PubMed  Google Scholar 

  118. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009 Aug; 54(6): 505–12

    Article  PubMed  CAS  Google Scholar 

  119. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003 May; 41(5): 1021–6

    Article  PubMed  CAS  Google Scholar 

  120. Savoia C, Touyz RM, Amiri F, et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008 Feb; 51(2): 432–9

    Article  PubMed  CAS  Google Scholar 

  121. Cherney DZ, Lai V, Scholey JW, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010 Feb; 33(2): 361–5

    Article  PubMed  CAS  Google Scholar 

  122. Palombo C, Malshi E, Morizzo C, et al. Arterial wave reflection during antihypertensive therapy with barnidipine: a 6-month, open-label study using an integrated cardiovascular ultrasound approach in patients with newly diagnosed hypertension. Clin Ther 2009 Dec; 31(12): 2873–85

    Article  PubMed  CAS  Google Scholar 

  123. Alem M, Milia P, Muir S, et al. Comparison of the effects of diuretics on blood pressure and arterial stiffness in patients with stroke. J Stroke Cerebrovasc Dis 2008 Nov–Dec; 17(6): 373–7

    Article  PubMed  Google Scholar 

  124. Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005 Aug; 19(4): 277–81

    Article  PubMed  CAS  Google Scholar 

  125. Heffernan KS, Suryadevara R, Patvardhan EA, et al. Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. Clin Cardiol 2011 Jan; 34(1): 39–44

    Article  PubMed  Google Scholar 

  126. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. Eur Heart J. 2007 Jun; 28(12): 1462–536

    PubMed  Google Scholar 

  127. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27 (11): 2121–58

    Google Scholar 

  128. Kelly RP, Gibbs HH, OśRourke MF, et al. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. Eur Heart J 1990 Feb; 11(2): 138–44

    PubMed  CAS  Google Scholar 

  129. Simkus GJ, Fitchett DH. Radial arterial pressure measurements may be a poor guide to the beneficial effects of nitroprusside on left ventricular systolic pressure in congestive heart failure. Am J Cardiol 1990 Aug; 66(3): 323–6

    Article  PubMed  CAS  Google Scholar 

  130. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 2011 Jun; 29(6): 1034–42

    Article  PubMed  CAS  Google Scholar 

  131. Van Bortel LM, De Backer T, De Buyzere M. How to treat arterial stiffness beyond blood pressure lowering?. J Hypertens 2011 Jun; 29(6): 1051–3

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This review was written independently; no company or institution supported it financially and there are no conflicts of interest. Some of the authors attended conferences, have given lectures, and have participated on advisory boards or other trials sponsored by various pharmaceutical companies.

C. Koumaras, T.D. Gossios, and N. Katsiki are supported by an educational grant from the Hellenic Atherosclerosis Society.

Author information

Authors and Affiliations

  1. Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece

    Charalambos Koumaras, Maria Tzimou, Theodora Griva, Thomas D. Gossios, Vasilios G. Athyros & Asterios Karagiannis

  2. Department of Nephrology, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece

    Eirini Stavrinou

  3. Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College London (UCL), Pond Street, London, NW3 2QG, UK

    Niki Katsiki &  Dimitri P. Mikhailidis

Authors
  1. Charalambos Koumaras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Tzimou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eirini Stavrinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Theodora Griva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas D. Gossios
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Niki Katsiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vasilios G. Athyros
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dimitri P. Mikhailidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Asterios Karagiannis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitri P. Mikhailidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koumaras, C., Tzimou, M., Stavrinou, E. et al. Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics. Am J Cardiovasc Drugs 12, 143–156 (2012). https://doi.org/10.2165/11599040-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11599040-000000000-00000

Keywords

Search

Navigation